Every 10-Q that PACS Group, Inc. (PACS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PACS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PACS filings page.
PACS Group reported sharply stronger quarterly results. For the three months ended March 31, 2026, revenue reached $1,420,494 thousand, up from $1,277,150 thousand a year earlier, while net income attributable to PACS rose to $80,695 thousand from $28,472 thousand. Diluted earnings per share were $0.50.
Operating cash flow was robust at $236,335 thousand, lifting cash and cash equivalents to $247,981 thousand and allowing a reduction of the line of credit balance to $45,000 thousand. The company operated 323 facilities with 35,516 beds across 17 states and continued to grow through targeted acquisitions.
PACS details significant lease and self‑insurance obligations, HUD‑insured long‑term debt, and ongoing DOJ and SEC investigations plus securities class and derivative actions that could lead to material costs or penalties. After quarter‑end, the board approved a $250 million share repurchase authorization.
PACS Group, Inc. (PACS) reported strong growth for the quarter and nine months ended September 30, 2025. Quarterly revenue rose to $1,344.6M from $1,026.3M a year earlier, driven by higher patient and resident service revenue. Net income attributable to PACS increased to $52.4M from $15.6M, and diluted EPS grew to $0.32 from $0.10.
For the first nine months of 2025, revenue reached $3,931.0M versus $2,881.8M in 2024, while net income attributable to PACS climbed to $131.8M from $18.6M. Operating cash flow improved to $407.6M, supporting a cash and cash equivalents balance of $355.7M as of September 30, 2025.
The company operates 320 facilities with 32,677 skilled nursing beds and 2,525 assisted living beds across multiple states, with revenue heavily dependent on government payors: Medicare accounted for about 32.7% and Medicaid 41.1% of Q3 2025 patient and resident service revenue.
PACS Group, Inc. (PACS), a skilled nursing and assisted living operator with 316 facilities and 34,627 total beds as of June 30, 2025, reported sharply improved results for the quarter. Total revenue rose to $1.31 billion from $935.7 million a year earlier, and operating income swung to $80.5 million from a loss. Net income attributable to PACS was $50.9 million, or $0.31 per diluted share, compared with a net loss of $31.9 million, or $(0.21) per share, in the prior-year quarter.
For the first six months of 2025, revenue reached $2.59 billion and net income attributable to PACS was $79.4 million, up from $2.9 million in the comparable 2024 period. Cash provided by operating activities more than doubled to $202.8 million, boosting cash and cash equivalents to $294.2 million from $157.7 million at year-end 2024. The company also reiterates that its 2024 quarterly financial statements were restated, mainly adjusting Medicare Part B revenue and certain lease classifications.
PACS Group, Inc. reports Q1 2025 results while reiterating prior restatements and detailing credit facility forbearance arrangements. For the three months ended March 31, 2025, total revenue was $1,277,150 thousand versus $919,836 thousand (as restated) a year earlier, driven by higher Medicare and Medicaid revenue. Net income attributable to PACS Group was $28,472 thousand, down from $34,817 thousand (as restated), as rent, labor and general and administrative expenses rose.
Operating cash flow strengthened to $150,244 thousand from $58,751 thousand, supporting a cash and cash equivalents balance of $287,512 thousand and total assets of $5,494,400 thousand. Total liabilities were $4,738,127 thousand, including significant long-term operating lease liabilities and debt, with stockholders’ equity of $750,228 thousand and 155,177,511 common shares outstanding as of March 31, 2025. The company restated Q1 2024 results, reducing patient and resident service revenue by $14,885 thousand and net income by $14,321 thousand mainly for Medicare Part B revenue and lease classification corrections, and describes multiple amendments and forbearance agreements under its Amended and Restated Credit Facility tied to technical events of default.
PACS Group, Inc. filed its Quarterly Report for the three and nine months ended September 30, 2024, restating earlier 2024 quarters after an audit committee investigation into Medicare Part B respiratory and certain other therapy revenue recognition. Management concluded that this revenue should not have been recognized under ASC 606, leading to restated March 31 and June 30, 2024 financials and a new refund liability of $83.987 million.
Q3 2024 revenue rose to $1.03 billion from $789.2 million a year earlier, but net income attributable to PACS decreased to $15.6 million from $19.9 million. For the first nine months, revenue grew to $2.88 billion from $2.26 billion, while net income fell sharply to $18.6 million from $78.7 million as the company absorbed higher costs, compliance-related adjustments and a higher tax provision.
Total assets increased to $4.52 billion, driven by property and right‑of‑use assets, and operating cash flow strengthened to $302.8 million. Lines of credit were reduced to zero from $520.0 million, aided by an initial public offering that raised $414.2 million and a follow‑on common stock offering of $95.3 million. PACS reported material weaknesses in internal control over financial reporting, found its disclosure controls ineffective as of September 30, 2024, and is implementing remediation measures while operating 276 facilities across multiple states.